Evaluation of the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side
National, Multicentre, Prospective, Observational Study, to Evaluate the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side
HIP50 is a national, multicentre, prospective, observational study, in patients presenting a first low energy per trochanteric hip fracture on one side and treated with Y-STRUT® device implanted on the contralateral proximal femur as percutaneous internal fixation to prevent contralateral hip fracture in case of osteoporosis.
The primary objective of this study is to evaluate the clinical efficacy of the studied medical device by measuring the frequency of patient with a fracture at the implantation site within 1 year after implantation.
A total of 50 patients from France will be enrolled (until December 2020) and followed up to 24 months.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
-
Ambérieu-en-Bugey, 프랑스, 01500
- Hôpital Privé d'Ambérieu
-
Clamart, 프랑스, 92140
- Hôpital Antoine Béclère
-
La Tronche, 프랑스, 38700
- Centre Hospitalier Universitaire Grenoble Alpes
-
Orléans, 프랑스, 45100
- Centre Hospitalier Régional Orléans
-
Tours, 프랑스, 37000
- Nouvelle Clinique de Tours Plus St Gatien
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patient of 60 years and older, according to CE indication;
- Patient with information form signed to participate in the study;
- Patients presenting a first low energy hip fracture on one side and having a Y-STRUT® device implanted on the contralateral hip between 0 and 120 days after the treatment of the fracture of the first hip;
Exclusion Criteria:
- Patient who refuse to participate to this study;
- Patient implanted with Y-STRUT® for another indication;
- Patient already enrolled in a clinical study, excluding his participation to HIP50.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Frequency of post-operative fracture [Clinical efficacy of the device]
기간: At 12 months
|
Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
|
At 12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Frequency of post-operative fracture [Clinical efficacy of the device]
기간: At 3 and 24 months
|
Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
|
At 3 and 24 months
|
|
Recording of concomitants treatments [safety and feasibility of the device]
기간: At 3, 12 and 24 months
|
Recording of all concomitants treatments: analgesic for pain, anti-osteoporotic treatment and other treatments.
|
At 3, 12 and 24 months
|
|
Pain [safety and feasibility of the device]
기간: At 3, 12 and 24 months
|
Self-evaluation of hip pain using VAS (Visual Analogue Scale), going from 0 (no pain) to 10 (maximum).
|
At 3, 12 and 24 months
|
|
Walking conditions [safety and feasibility of the device]
기간: At 3, 12 and 24 months
|
Assessment of resumption of weight-bearing (yes/no, aid)
|
At 3, 12 and 24 months
|
|
Recording of adverse events and device effects [safety and feasibility of the device]
기간: At 3, 12 and 24 months
|
Recording of the medical device vigilance: all serious adverse events, all adverse events linked to the device or the operative technique, and any other important event reported.
|
At 3, 12 and 24 months
|
|
Surgical procedure duration [learning curve of the procedure]
기간: At the end of the inclusion period (24 months from the first included patient)
|
Measuring mean/median intervention duration of each procedure.
Then, all the durations of successive procedures will be compared among all the investigators.
|
At the end of the inclusion period (24 months from the first included patient)
|
|
Hospitalisation duration [learning curve of the procedure]
기간: At the end of the inclusion period (24 months from the first included patient)]
|
Measuring mean/median hospitalisation duration.
Then, all the durations of successive hospitalisations will be compared among all the investigators.
|
At the end of the inclusion period (24 months from the first included patient)]
|
|
Rate of complications [learning curve of the procedure]
기간: At the end of the inclusion period (24 months from the first included patient)
|
Assessing types and frequencies of procedures complications (per-op and post-op).
Then, all the rate of complications will be compared among all the investigators.
|
At the end of the inclusion period (24 months from the first included patient)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- HIP50
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .